蘭尼單抗
 | 此條目沒有列出任何參考或來源。 (2014年3月10日) |
 | 此條目可參照英語維基百科相應條目來擴充。 (2023年12月3日) |
| 單克隆抗體 | |
|---|---|
| 種類 | Fab片段 |
| 目標 | 血管內皮生長因子A（VEGF-A） |
| 臨床資料 | |
| 商品名 | Lucentis, others |
| 生物相似藥 | Ranibizumab-nuna,[1] Ranibizumab-eqrn,[2] Byooviz,[1][3] Cimerli,[2] Ranivisio,[4] Susvimo,[5] Ximluci[6] |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607044 |
| 核准狀況 |
|
| 懷孕分級 | |
| 給藥途徑 | 靜脈注射 |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 |
|
| 藥物動力學數據 | |
| 生物半衰期 | 約9天[10] |
| 識別資訊 | |
| CAS號 | 347396-82-1  |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| 化學資訊 | |
| 化學式 | C2158H3282N562O681S12 |
| 摩爾質量 | 48,379.97 g·mol−1 |
蘭尼單抗（英語：Ranibizumab，也譯為雷珠單抗，商品名Lucentis）是一種單克隆抗體片段（FAB），其與貝伐單抗（bevacizumab）是從相同親本鼠抗體獲得。它比母體分子小得多，能更緊密的結合到血管內皮生長因子-A(VEGF-A)。它是一種血管生成抑制劑(angiogenesis inhibitor)，已被批准用於治療的「濕」型老年黃斑變性。
參考資料
[編輯]- ^ 1.0 1.1 1.2 Byooviz Nuna- ranibizumab injection, solution. DailyMed. 2022-04-27 [2022-08-02]. （原始內容存檔於2022-08-03）.
- ^ 2.0 2.1 2.2 Cimerli- ranibizumab-eqrn injection, solution. DailyMed. 2022-10-19 [2023-01-21]. （原始內容存檔於2023-01-21）.
- ^ 3.0 3.1 Byooviz EPAR. European Medicines Agency. 2021-06-23 [2021-09-09]. （原始內容存檔於2021-09-10）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ 4.0 4.1 Ranivisio EPAR. European Medicines Agency (EMA). 2022-06-20 [2022-10-06]. （原始內容存檔於2022-10-06）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ 5.0 5.1 Susvimo- ranibizumab injection, solution. DailyMed. [2021-12-19]. （原始內容存檔於2021-12-19）.
- ^ 6.0 6.1 Ximluci EPAR. European Medicines Agency. 2022-09-14 [2023-03-03]. （原始內容存檔於2023-03-13）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ 7.0 7.1 AusPAR: Ranibizumab. Therapeutic Goods Administration (TGA). 2014-12-09 [2021-09-20]. （原始內容存檔於2021-09-21）.
- ^ 8.0 8.1 https://www.tga.gov.au/resources/auspmd/byooviz [裸露網址]
- ^ Summary Basis of Decision - Byooviz. Health Canada. 2022-08-12 [2022-09-29]. （原始內容存檔於2022-09-29）.
- ^ 10.0 10.1 Lucentis- ranibizumab injection, solution. DailyMed. [2021-09-20]. （原始內容存檔於2021-09-21）.
- ^ Lucentis EPAR. European Medicines Agency. 2018-09-17 [2021-09-09]. （原始內容存檔於2021-09-10）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
外部連結
[編輯]- 官方網站 Genentech